VIP and colitis: In a model of TNBS-induced colitis, which closely parallels the immune activation in Crohn's disease, injection of tol-DCs treated with Vasoactive Intestinal Peptide (VIP) [38] significantly ameliorated the clinical and histopathology severity of colitis in mice.